Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.94
EPS est.
$-1.04
EPS surprise
+9.62%
1-day move
+1.22%
Celldex Therapeutics reported a narrower loss than analysts expected, which contributed to a positive stock reaction, with shares rising 1.22%. However, the company did not provide revenue figures or guidance for future performance, leaving some uncertainty for investors. The lack of revenue and management commentary may lead to cautious sentiment among investors moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | $-1.01 | +9.62% |
| Revenue | — | $1M | — |
No transcript is on record, and the analysis is based on numerical results only.
Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $3 billion, its work is crucial in the health care sector, particularly as the demand for effective treatments continues to rise.
Last quarter
In Q1-2026, Celldex reported an EPS of $-1.18, which was worse than the expected $-1.10. The stock fell 3.11% the following day, indicating investor disappointment.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-3.61%
Avg 1-day reaction
+3.80%
Analysts anticipate a challenging quarter for Celldex, with expectations of a loss and modest revenue. The consensus EPS is set at $-1.01, reflecting ongoing concerns about the company's financial trajectory.
Bull case
If Celldex can exceed EPS expectations and show signs of revenue growth, it could signal a turnaround in investor confidence and lead to a positive stock reaction.
Bear case
Conversely, if the company reports a larger loss than expected or fails to generate significant revenue, it could further erode investor trust and lead to a sharp decline in the stock price.
Key metrics to watch
EPS
$-1.01Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Celldex's EPS come in better than the consensus estimate of $-1.01?
A better-than-expected EPS could boost investor confidence and lead to a positive stock reaction.
Q2
What revenue figures will Celldex report, and how do they compare to the $1M consensus?
Revenue performance is critical for understanding market demand and the company's growth trajectory.
Est. EPS
$6.10
Est. Rev
$5.0B
Impl. Move
±5.3%
Why consensus could be wrong
The Street may underestimate Celldex's potential for revenue growth, as recent developments in its pipeline could lead to unexpected sales.
Supporting evidence
The options market is pricing a 23.6% move, indicating significant uncertainty that may not align with the actual performance.
Celldex has a history of surprising investors, with a 50% EPS beat rate in recent quarters.
Key risk
If revenue comes in above $1M, it could challenge the current bearish sentiment and shift investor expectations.
Pre-commit to what would confirm each case.
The market is debating whether Celldex can stabilize its financial performance after a series of disappointing earnings.
Bull confirmed if
Reporting an EPS loss of less than $-1.01 and revenue exceeding $1M would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-1.01 and revenue below $1M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±23.6%
Historical Avg
±5.5%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±23.6% while CLDX has averaged ±5.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
33.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Celldex beats expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
If the company misses expectations, history suggests a potential decline of about 5.80%, reflecting ongoing concerns.
The lines on the call that would change the story.